PRN Meeting: August 11, 2021 Jointly provided by the Medical Society of the State of New York, at a Zoom webinar, 7:00 p.m. to 9:00 p.m (EST).

Target Audience:

Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.

Course Director: James F. Braun, DO, President, Physicians' Research Network

Moderator: William M. Valenti, MD, Chair, Infectious Diseases Committee of the Medical Society of the State of New York

Guest Speakers and Presentations:

Advances in COVID-19 Management

Jürgen Rockstroh, MD

Head of Infectious Diseases
University Hospital Bonn
Bonn, Germany

What clinicians and researchers have learned over these past 18 months during the COVID-19 pandemic is of critical importance to us now and may help us change outcomes for this as well as future pandemics.  Jügen Rockstroh’s thoughtful presentation will provide an update on COVID-19 epidemiology, diagnostics, treatments and vaccines from a European perspective.

Learning Objectives:

At the completion of this educational session, participants will:
1. Understand current COVID-19 epidemiology.
2. Be aware of newest developments in COVID-19 diagnostics and treatments.
3. Know about currently available SARS-Cov-2 vaccines.
4. Understand the impact of vaccination programs on pandemic control.

Highlights from the Virtual IAS Conference on HIV Science 2021

W. David Hardy, MD, AAHIVS

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Keck School of Medicine of USC
Los Angeles

This program presented by David Hardy is a review of highlights from the Virtual IAS Conference on HIV Science 2021, including clinically relevant advances in antiretroviral therapy, metabolic effects, as well as investigational agents for HIV treatment and prevention.

Learning Objectives:

At the completion of this educational session, participants will:
1. Be able to discuss new clinically relevant advances in antiretroviral therapy and prevention strategies for HIV.
2. Learn about new drugs for HIV treatment and prevention.
3. Recognize emerging metabolic effects associated with antiretrovirals used for treatment and prevention of HIV.

Accreditation Statement: This activity has been planned and implemented in accordance with the Accreditation Requirements and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). The Medical Society of the State of New York (MSSNY) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.

The Medical Society of the State of New York (MSSNY) designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:

Dr. Braun (Planner/Course Director) has no relevant financial relationships to disclose. Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. Dr. Jürgen Rockstroh (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Honorarium Recipient from: Gilead, Janssen, Merck, and ViiV. Dr. Rockstroh will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review. Dr. W. David Hardy(Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Advisory Board Member to: Gilead, Merck, and ViiV; Consultant to: Enochian Biosciences, and ViiV. Dr. Hardy will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.

Financial Support:

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare